Literature DB >> 4027811

Psychosis due to transdermally administered scopolamine.

G W MacEwan, R A Remick, J A Noone.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4027811      PMCID: PMC1346539     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  6 in total

1.  Transdermal scopolamine and toxic psychosis.

Authors:  K J Rodysill; J B Warren
Journal:  Ann Intern Med       Date:  1983-04       Impact factor: 25.391

Review 2.  Rate-controlled drug delivery.

Authors:  P Goldman
Journal:  N Engl J Med       Date:  1982-07-29       Impact factor: 91.245

3.  The anticholinergic intoxication syndrome: diagnosis and treatment.

Authors:  A L Johnson; L E Hollister; P A Berger
Journal:  J Clin Psychiatry       Date:  1981-08       Impact factor: 4.384

4.  Physostigmine. Its use in acute anticholinergic syndrome with antidepressant and antiparkinson drugs.

Authors:  R P Granacher; R J Baldessarini
Journal:  Arch Gen Psychiatry       Date:  1975-03

5.  Influence of sickle hemoglobinopathies on growth and development.

Authors:  O S Platt; W Rosenstock; M A Espeland
Journal:  N Engl J Med       Date:  1984-07-05       Impact factor: 91.245

6.  Physostigmine salicylate as an antidote.

Authors:  M Daunderer
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1980-12
  6 in total
  2 in total

Review 1.  Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.

Authors:  Zohar Nachum; Avi Shupak; Carlos R Gordon
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 2.  Neurological and psychiatric adverse effects of anaesthetics: epidemiology and treatment.

Authors:  J M Klafta; J P Zacny; C J Young
Journal:  Drug Saf       Date:  1995-11       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.